Completed Access to Information Requests

Follow:

  • RSS
  • Cite
About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Report Type

Organization

Disposition

Year

Month

Found 62170 record(s)

Req # A-2021-001996

Briefing notes and attachments regarding the January 17, 2022 authorization of PAXLOVID TM for patients with mild to moderate COVID-19 at high risk of developing serious disease from November 1, 2021 to February 1, 2022.

Organization: Health Canada

12 page(s)
February 2024

Req # A-2022-000881

All complaints posted against Lifeline Pharmaceuticals - in relation to health product advertising incidents. All information in relation to incidents received by Health Canada and those referred to an Advertising Preclearance Agency (APA) from 2021-01-01- 2022-09-27 in regards to product Misoprostol. All information in relation to complaints regarding the direct-to-consumer advertising of unauthorized claims.

Organization: Health Canada

720 page(s)
February 2024

Req # A-2022-000919

The Rothmans, Benson & Hedges submission in response to consultation on the proposed Regulations Amending the Tobacco Products Regulations published in the Canada Gazette Part I on June 11, 2022.

Organization: Health Canada

59 page(s)
February 2024

Req # A-2022-000996

The disclosable inspection document(s) listing the Inspector’s detailed observations, conditions found, and any follow-up expected by Health Canada for the human drugs drug establishment licence Good Pharmacovigilance Practices (GVP) inspection of the Gilead Sciences Canada facility (Site A) on Mississauga Road, Mississauga, Ontario starting around 19 July 2021. Reference Number 502703.

Organization: Health Canada

56 page(s)
February 2024

Req # A-2022-001027

The number of prescription requests for psychedelic drugs that were made and the number of prescriptions that were authorized by Health Canada since January 5, 2022.

Organization: Health Canada

4 page(s)
February 2024

Req # A-2022-001281

All communications with Facebook regarding any discussions/requests to censor/suspend/ban/promote/throttle/shadow ban an account or particular post, since January 1, 2020.

Organization: Health Canada

2 page(s)
February 2024

Req # A-2022-001559

Internal correspondence related to the Minister of Health‘s letter to provincial and territorial health ministers concerning patients being charged for medically necessary care. Related to the drafting of the letter, requests for information related to its contents, and discussions of when to send it. Between the dates of February 6, 2023 and March 10, 2023.

Organization: Health Canada

168 page(s)
February 2024

Req # A-2022-001649

Advise whether this desmopressin Abbreviated New Drug Submission (ANDS), which was accepted into review on or after March 1, 2022, but before December 1, 2022, has: received a Notice of Deficiency (NOD); received a Notice of Non-Compliance (NON); received a NOD-Withdrawal (NOD-W); received a NON-Withdrawal (NON-W); or is on Patent Hold. If this desmopressin ANDS has received any of the notices listed above, or if it was put on Patent Hold, advise of the month and year that the notice/hold was issued; and provide a copy of the correspondence.

Organization: Health Canada

17 page(s)
February 2024

Req # A-2023-000171

The Minister’s meeting records in 2022, 2023 with drug companies and/or trade associations which mention drug pricing and/or the Patented Medicine Prices Review Board (PMPRB). Provide 2022, 2023 records prepared for the Minister on PMPRB proposed drug lowering plans and challenges to that plan. Provide 2023 response to PMPRB members resignations and to expert health professionals concerned about the Minister’s pausing and intervening on the PMPRB plans.

Organization: Health Canada

17 page(s)
February 2024

Req # A-2023-000268

Module 5.2 (Tabular Listing of all Clinical Studies) for pms-Iron Sucrose that received a Notice of Compliance on 30 July 2020. Drug Identification Number (DIN) 02502917.

Organization: Health Canada

2 page(s)
February 2024
Date modified: